Damora Therapeutics, Inc. — All Filings
315 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-Q
144
144/A
3
4
424B3
424B4
424B5
8-A12B
8-K
8-K/A
ARS
CERT
CORRESP
D
DEF 14A
DEFA14A
DRS
EFFECT
PRE 14A
S-1
S-1/A
S-3
S-3ASR
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SCHEDULE 13D
SCHEDULE 13D/A
SCHEDULE 13G
SCHEDULE 13G/A
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 4 | 4 | 0000950170-24-076183 | Jun 21, 2024 | Jun 20, 2024 |
| DEF 14A | DEF 14A | 0000950170-24-049811 | Apr 29, 2024 | Jun 20, 2024 |
| 10-Q | 10-Q | 0000950170-24-049808 | Apr 29, 2024 | Mar 31, 2024 |
| PRE 14A | PRE 14A | 0000950170-24-044763 | Apr 16, 2024 | Jun 20, 2024 |
| 8-K | 8-K | 0000950170-24-036391 | Mar 26, 2024 | Mar 22, 2024 |
| 10-K | 10-K | 0000950170-24-028610 | Mar 8, 2024 | Dec 31, 2023 |
| S-8 | S-8 | 0000950170-24-028663 | Mar 8, 2024 | — |
| SCHEDULE 13G/A | — | 0001995601-24-000002 | Feb 9, 2024 | — |
| 4 | 4 | 0000950170-24-002429 | Jan 5, 2024 | Jan 3, 2024 |
| 4 | 4 | 0000950170-24-002433 | Jan 5, 2024 | Jan 3, 2024 |
| 4 | 4 | 0000950170-24-002430 | Jan 5, 2024 | Jan 3, 2024 |
| 8-K | 8-K | 0000950170-23-072258 | Dec 21, 2023 | — |
| 10-Q | 10-Q | 0000950170-23-059367 | Nov 6, 2023 | Sep 30, 2023 |
| 8-K | 8-K | 0000950170-23-054508 | Oct 23, 2023 | — |
| SC 13G | GALECTO13G | 0001995601-23-000002 | Oct 3, 2023 | — |
| 144 | — | 0000947871-23-000972 | Oct 2, 2023 | — |
| 8-K | 8-K | 0000950170-23-051118 | Oct 2, 2023 | Sep 27, 2023 |
| 144 | — | 0000947871-23-000970 | Oct 2, 2023 | — |
| 144 | — | 0000947871-23-000971 | Oct 2, 2023 | — |
| 144 | — | 0000947871-23-000969 | Oct 2, 2023 | — |
| 8-K | 8-K | 0000950170-23-049919 | Sep 26, 2023 | Sep 20, 2023 |
| SC 13D/A | AMENDMENT NO. 6 | 0000947871-23-000940 | Sep 18, 2023 | — |
| SC 13D/A | AMENDMENT NO. 5 | 0000947871-23-000922 | Sep 5, 2023 | — |
| 144 | — | 0000947871-23-000909 | Aug 30, 2023 | — |
| 144 | — | 0000947871-23-000910 | Aug 30, 2023 | — |
| 144 | — | 0000947871-23-000911 | Aug 30, 2023 | — |
| 144 | — | 0000947871-23-000912 | Aug 30, 2023 | — |
| 144/A | — | 0000947871-23-000888 | Aug 21, 2023 | — |
| 144 | — | 0000947871-23-000883 | Aug 21, 2023 | — |
| 144 | — | 0000947871-23-000884 | Aug 21, 2023 | — |
| 144 | — | 0000947871-23-000886 | Aug 21, 2023 | — |
| 144 | — | 0000947871-23-000887 | Aug 21, 2023 | — |
| SC 13D/A | AMENDMENT NO. 4 | 0000947871-23-000872 | Aug 17, 2023 | — |
| 4 | — | 0000947871-23-000873 | Aug 17, 2023 | Aug 15, 2023 |
| 144 | — | 0000947871-23-000864 | Aug 15, 2023 | — |
| 144 | — | 0000947871-23-000865 | Aug 15, 2023 | — |
| 8-K | 8-K | 0000950170-23-042631 | Aug 15, 2023 | — |
| 144 | — | 0000947871-23-000866 | Aug 15, 2023 | — |
| 144 | — | 0000947871-23-000867 | Aug 15, 2023 | — |
| 4 | — | 0000947871-23-000809 | Aug 2, 2023 | Jul 31, 2023 |
| SC 13D/A | AMENDMENT NO. 3 | 0000947871-23-000808 | Aug 2, 2023 | — |
| 144 | — | 0000947871-23-000796 | Jul 31, 2023 | — |
| 144 | — | 0000947871-23-000795 | Jul 31, 2023 | — |
| 144 | — | 0000947871-23-000797 | Jul 31, 2023 | — |
| 10-Q | 10-Q | 0000950170-23-035925 | Jul 31, 2023 | Jun 30, 2023 |
| 144 | — | 0000947871-23-000798 | Jul 31, 2023 | — |
| 4 | — | 0000947871-23-000789 | Jul 27, 2023 | Jul 25, 2023 |
| 144 | — | 0000947871-23-000780 | Jul 25, 2023 | — |
| 144 | — | 0000947871-23-000781 | Jul 25, 2023 | — |
| 144 | — | 0000947871-23-000782 | Jul 25, 2023 | — |